<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1600">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02050100</url>
  </required_header>
  <id_info>
    <org_study_id>SKTCTCH0001</org_study_id>
    <nct_id>NCT02050100</nct_id>
  </id_info>
  <brief_title>Biomarkers for Diagnosis of Lung Cancer</brief_title>
  <official_title>Biomarkers for Diagnosis of Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Medical (Beijing) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Medical (Beijing) Co., Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study goal is to collect blood samples from individuals at risk for lung cancer in order
      to identify protein markers for diagnosis of lung cancer in the Chinese population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Identification of blood biomarkers for detection of lung cancer</measure>
    <time_frame>6 months after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>SK Telecom will utilize 15 single-plex quantitative Polymerase Chain Reaction (qPCR) assays to analyze an initial set of 300 clinical samples in China.  SomaLogic will analyze these samples on the SOMAscan array (&gt;1000 proteins) for additional lung cancer biomarker candidates.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Neoplasm</condition>
  <arm_group>
    <arm_group_label>Lung Cancer</arm_group_label>
    <description>Early-late stage primary lung cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lung Neoplasm</arm_group_label>
    <description>Benign non-calcified pulmonary nodules</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Two 10ml blood samples (serum and plasma) from the patient will be analyzed for protein
      biomarkers associated with lung cancer diagnosis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 300 patients will be recruited from hospital pulmonary clinics. The study
        participants will have pulmonary nodules suspicious for lung cancer and a bronchial biopsy
        diagnosis of NSCLC or probable benign. Approximately half of the patients will be cases
        and half controls.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults â‰¥ 18 years of age

          -  Patients referred to pulmonologists, oncologists, or thoracic surgeons for diagnosis
             of suspicious pulmonary nodules as either lung cancer or benign and undergoing
             bronchoscopic biopsy

          -  Patients will be enrolled if the result of the bronchoscopic biopsy is a diagnosis of
             NSCLC or benign pulmonary nodule

          -  Cases: Patients with untreated non-small cell lung cancer, i.e. primary lung
             adenocarcinoma or squamous cell carcinoma of early

          -  Computed tomography or X-Ray is available and shows a suspicious pulmonary nodule

          -  A biopsy or surgical resection to clarify the nature of the lung nodule is available
             (NSCLC or benign, including histological diagnosis) in both groups

          -  Controls: Patients must be available for a 6 month follow-up to confirm benign
             diagnosis

          -  A serum and plasma sample was collected prior to any treatment of the lung nodule
             beyond biopsy

          -  No other cancer diagnosis in the last 5 years excluding non-melanoma skin cancer

          -  Patients must be fully informed of the investigational nature of the procedure and
             sign an informed consent.

        Exclusion Criteria:

          -  Prior treatment for lung cancer by chemotherapy or surgery (excluding biopsy)

          -  Patients with benign nodules who are not able or willing to have a 6-month follow-up
             visit to confirm benign diagnosis

          -  Diagnosis or treatment of other cancer in the last 5 years excluding non-melanoma
             skin cancer. In the judgment of the clinical investigator, patients who are likely to
             be non compliant or uncooperative during the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunxue Bai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Hospital Fudan Universit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoju Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan province People's hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shang Hai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunxue Bai</last_name>
      <phone>(86) 13681971807</phone>
      <email>bai.chunxue@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Chunxue Bai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan province People's hospital</name>
      <address>
        <city>Zheng zhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoju Zhang</last_name>
      <phone>(86) 15837101166</phone>
      <email>zhangxiaoju1010@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoju Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>January 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary lung adenocarcinoma Stages I, II, IIA,  IIIB</keyword>
  <keyword>squamous cell carcinoma Stages I, II, IIA, IIIB</keyword>
  <keyword>benign non-calcified pulmonary nodules</keyword>
  <keyword>early detection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
